Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress [Financial Post (Toronto, Onta...
Organovo Holdings, Inc. (ONVO)
NASDAQ:AMEX Investor Relations:
organovo.com/about/contact/investor-relations
Company Research
Source: Financial Post
company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis, based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the presentation of preclinical data related to the company's FXR314 development program in its proprietary 3D human tissue models of Crohn's disease and ulcerative colitis at the Crohn's and Colitis Congress being held January 25-27, 2024 in Las Vegas, Nevada. Article content FXR314 is a clinical-stage potent, selective, orally administered non-bile acid FXR agonist being developed as a novel therapeutic approach for IBD. Article content “There is a critical need for novel approaches to treat inflammatory bowel disease (IBD) that extend beyond modulating the immune response targeted by current pharmacological therapies. These data underscore the potential of FXR314 as a unique treatment approach to IBD given its demonstrated multifaceted activity profile, especially in direct
Show less
Read more
Impact Snapshot
Event Time:
ONVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONVO alerts
High impacting Organovo Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
ONVO
News
- Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) [Yahoo! Finance]Yahoo! Finance
- Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)GlobeNewswire
- Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering [Yahoo! Finance]Yahoo! Finance
ONVO
Sec Filings
- 5/14/24 - Form 424B4
- 5/13/24 - Form 8-K
- 5/10/24 - Form 424B4
- ONVO's page on the SEC website